# SABR-ATAC: A Trial of TGF-beta Inhibition and Stereotactic Ablative Radiotherapy for Early Stage Non-small Cell Lung Cancer

> **NCT02581787** · PHASE1,PHASE2 · COMPLETED · sponsor: **Maximilian Diehn** · enrollment: 28 (actual)

## Conditions studied

- Stage IA Non-Small Cell Lung Carcinoma
- Stage IB Non-Small Cell Lung Carcinoma

## Interventions

- **BIOLOGICAL:** Fresolimumab
- **RADIATION:** Stereotactic Body Radiation Therapy

## Key facts

- **NCT ID:** NCT02581787
- **Lead sponsor:** Maximilian Diehn
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-08
- **Primary completion:** 2023-03-02
- **Final completion:** 2023-03-02
- **Target enrollment:** 28 (ACTUAL)
- **Last updated:** 2024-03-27

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02581787

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02581787, "SABR-ATAC: A Trial of TGF-beta Inhibition and Stereotactic Ablative Radiotherapy for Early Stage Non-small Cell Lung Cancer". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT02581787. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*